Predictive Value of Venous Excess Ultrasound Score in Management of Cardiorenal Patients

NCT05368766 | Unknown

• 1 other identifier: VExUS score in cardiorenal
• Study Type: observational
• Target: 60
• Locations: 0 countries
• Sites: N/A

Brief Summary

To assess predictive value of venous excess ultrasound score in cardiorenal patient management

Conditions

Cardio-Renal Syndrome

Outcome Measures

Primary Outcomes (1)

• response to diuretic

  Response to diuretic therapy in cardiorenal patients (failure to produce 0.5 ml/kg/h of urine after administration of at least double the dose of the patient's home diuretic therapy or after administration of 250 mg of Lasix and 10 mg of Metolazone in diuretic naïve patientfailure to produce 0.5 ml/kg/h of urine after administration of at least double the dose of the patient's home diuretic therapy or after administration of 250 mg of Lasix and 10 mg of Metolazone in diuretic naïve patient)

  Baseline

Secondary Outcomes (3)

• Length of ICU stay

  Through study completion, an average of 2 weeks

• Worsening renal function

  Through study completion, an average of 2 weeks

• Need to ultrafiltration

  Baseline

Interventions

VExUS score OTHER

The venous excess ultrasound (VExUS) score incorporates hepatic venous, intrarenal venous Doppler, inferior vena cava (IVC) assessment, and portal vein Doppler

Diuretic Effect DRUG

Response to diuretic therapy

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Cardiorenal patients above 18 years old

You may qualify if:

• Patients with congestive heart failure and GFR less than 100 ml/minute

You may not qualify if:

• Patients below 18 years old. Patients with liver cirrhosis and portal hypertension. Patients with IVC thrombus. Patients with inadequate ultrasonography window.

Sponsors & Collaborators

• Assiut University: lead

Related Publications (6)

• Rangaswami J, Bhalla V, Blair JEA, Chang TI, Costa S, Lentine KL, Lerma EV, Mezue K, Molitch M, Mullens W, Ronco C, Tang WHW, McCullough PA; American Heart Association Council on the Kidney in Cardiovascular Disease and Council on Clinical Cardiology. Cardiorenal Syndrome: Classification, Pathophysiology, Diagnosis, and Treatment Strategies: A Scientific Statement From the American Heart Association. Circulation. 2019 Apr 16;139(16):e840-e878. doi: 10.1161/CIR.0000000000000664.

  PMID: 30852913 BACKGROUND

• Zhang L, Chen Z, Diao Y, Yang Y, Fu P. Associations of fluid overload with mortality and kidney recovery in patients with acute kidney injury: A systematic review and meta-analysis. J Crit Care. 2015 Aug;30(4):860.e7-13. doi: 10.1016/j.jcrc.2015.03.025. Epub 2015 Apr 9.

  PMID: 25979272 BACKGROUND

• Rola P, Miralles-Aguiar F, Argaiz E, Beaubien-Souligny W, Haycock K, Karimov T, Dinh VA, Spiegel R. Clinical applications of the venous excess ultrasound (VExUS) score: conceptual review and case series. Ultrasound J. 2021 Jun 19;13(1):32. doi: 10.1186/s13089-021-00232-8.

  PMID: 34146184 BACKGROUND

• Bhardwaj V, Vikneswaran G, Rola P, Raju S, Bhat RS, Jayakumar A, Alva A. Combination of Inferior Vena Cava Diameter, Hepatic Venous Flow, and Portal Vein Pulsatility Index: Venous Excess Ultrasound Score (VEXUS Score) in Predicting Acute Kidney Injury in Patients with Cardiorenal Syndrome: A Prospective Cohort Study. Indian J Crit Care Med. 2020 Sep;24(9):783-789. doi: 10.5005/jp-journals-10071-23570.

  PMID: 33132560 BACKGROUND

• Shimada S, Hirose T, Takahashi C, Sato E, Kinugasa S, Ohsaki Y, Kisu K, Sato H, Ito S, Mori T. Pathophysiological and molecular mechanisms involved in renal congestion in a novel rat model. Sci Rep. 2018 Nov 14;8(1):16808. doi: 10.1038/s41598-018-35162-4.

  PMID: 30429498 BACKGROUND

• Neal CR, Arkill KP, Bell JS, Betteridge KB, Bates DO, Winlove CP, Salmon AHJ, Harper SJ. Novel hemodynamic structures in the human glomerulus. Am J Physiol Renal Physiol. 2018 Nov 1;315(5):F1370-F1384. doi: 10.1152/ajprenal.00566.2017. Epub 2018 Jun 20.

  PMID: 29923763 BACKGROUND

MeSH Terms

Conditions

Cardio-Renal Syndrome

Interventions

Diuretics

Condition Hierarchy (Ancestors)

Renal Insufficiency; Kidney Diseases; Urologic Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Male Urogenital Diseases; Heart Failure; Heart Diseases; Cardiovascular Diseases

Intervention Hierarchy (Ancestors)

Natriuretic Agents; Physiological Effects of Drugs; Pharmacologic Actions; Chemical Actions and Uses

Study Officials

• Abdallah I. Kelany, MD

  university

  STUDY DIRECTOR

Central Study Contacts

Hany A. Habib, Master

CONTACT

01010963829; hanysaid1690@gmail.com

Ahmad B. Abdelrehim, MD

CONTACT

01009820300; ahmadbahie@yahoo.com

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Target Duration: 7 Days
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal Investigator

Study Record Dates

• First Submitted: April 13, 2022
• First Posted: May 10, 2022
• Study Start: June 1, 2022
• Primary Completion: June 1, 2024
• Study Completion: August 1, 2024
• Last Updated: May 10, 2022

Record last verified: 2022-05